Mainstream

Niagen Bioscience increases FY25 net sales outlook to 25% to 30% year-over-year growth

Niagen Bioscience increases FY25 net sales outlook to 25% to 30% year-over-year growth

Post ContentnageRead More

You might also be interested in reading Barcelona-based Neurosurgical Specialist Awarded Designation of International Center of Excellence for Ehlers-Danlos Syndrome.

October 6, 2025
In Mainstream